MERS-CoV is an emerging zoonotic virus that is considered to be one of the major public health threats. Since 2012, there have been consistent monthly cases of MERS-CoV causing severe respiratory illness, resulting in the death of approximately 35% of confirmed patients. It is believed that the virus is transmitted from camels in Middle Eastern countries through contact between humans and animals. The viral genome structure provides crucial insights into its pathogenicity and associated virulence factors.
However, recent studies indicate that our understanding of the development of novel therapeutic strategies aimed at inducing antiviral immunity remains limited. The severity of MERS-CoV infection underscores the urgent need for effective therapeutic approaches. The ongoing threat to global public health posed by MERS-CoV, coupled with the need for novel therapeutic strategies, has driven the development of animal models that can reliably reproduce MERS-CoV-associated pathology in human infections.
With extensive expertise and cutting-edge resources, Creative Diagnostics is committed to providing reliable animal models for MERS-CoV infection. This enables clients worldwide to gain a deeper understanding of the virus's complex mechanisms. Backed by a dedication to scientific excellence, these models show great promise in advancing research into the intricate pathogenesis of MERS-CoV, assessing potential therapeutic interventions and accelerating the development of effective strategies to combat this potent virus.
Creative Diagnostics' MERS-CoV animal models primarily include the MERS-CoV Virus Tracheal Intubation Infection Rhesus Monkey Model, and the MERS-CoV Virus Intranasal Infection Mouse Model. By addressing key conditions such as mortality rates associated with severe respiratory disease, the absence of neurological complications at high viral loads and sustained high levels of viral replication in the lungs, Creative Diagnostics' animal models simulate human infection with MERS-CoV. They retain the innate expression of the MERS-CoV host receptor DPP4 and feature genetically modifiable host genes, making them suitable for vaccine and therapeutic response studies.
Creative Diagnostics' animal models provide researchers with a controlled experimental platform on which to study viral behaviour, transmission, immune responses, and potential therapeutic approaches. Creative Diagnostics also offers a range of services to support MERS-CoV animal model research, including pathological analysis, immune response profiling, vaccine and antiviral compound efficacy testing, and data analysis and interpretation.
Creative Diagnostics will be showcasing these preclinical services, alongside their comprehensive suite of viral and bacterial infection models, at the upcoming ASM Microbe 2026 conference in Washington, D.C., from June 4-7, at booth #1608. Attendees are invited to meet with their scientific team to discuss custom study designs and partnership opportunities.
For more information about the MERS-CoV Animal Model services or to request a consultation, please visit https://antiviral.creative-diagnostics.com/mers-cov-animal-model.html.
About Creative Diagnostics
Headquartered in New York, Creative Diagnostics is a consulting and experimental service provider specializing in virology and microbiology. The company provides comprehensive solutions to conquer obstacles in virology and microbiology research, from high-security infrastructure provision, biosafety regulation elucidation, to expert viral system assistance.
